HIGH-INCIDENCE OF CHEMOTHERAPY-INDUCED ACRAL ERYTHEMA IN FEMALE-PATIENTS WITH NON-HODGKINS-LYMPHOMA TREATED WITH THE VACOP-B REGIMEN

Citation
H. Ogawa et al., HIGH-INCIDENCE OF CHEMOTHERAPY-INDUCED ACRAL ERYTHEMA IN FEMALE-PATIENTS WITH NON-HODGKINS-LYMPHOMA TREATED WITH THE VACOP-B REGIMEN, Leukemia & lymphoma, 29(1-2), 1998, pp. 171
Citations number
22
Categorie Soggetti
Hematology,Oncology
Journal title
ISSN journal
10428194
Volume
29
Issue
1-2
Year of publication
1998
Database
ISI
SICI code
1042-8194(1998)29:1-2<171:HOCAEI>2.0.ZU;2-X
Abstract
Seven patients, all females out of 29 with non-Hodgkin's lymphoma (NHL )(16 males and 13 females) treated with the VACOP-B regimen utilizing granulocyte-colony stimulating factor (G-CSF) support developed chemot herapy-induced acral erythema (CAE). In contrast, none of 32 patients with NHL who were treated with CHOP, MACOP-B, or biweekly CHOP regimen s without G-CSF developed CAE. Total dose intensities of VACOP-B regim en were higher than those of the three other regimens. However, no sig nificant difference in dose intensities of each drug in the patients t reated with the VACOP-B regimen was found between male and female pati ents and between female patients with or without CAE. The cause of the high incidence of CAE (7/13) in the female patients treated with VACO P-B regimen remains unknown. However, female sex hormones may increase susceptibility to CAE. Since the occurrence of CAE interrupts intensi ve chemotherapy and reduces the cure rate, high risk patients for CAE should be carefully monitored for early symptoms and signs of CAE and should be treated early and appropriately.